Summary A correlation analysis was performed on 223 breast carcinomas to assess the relationships between gene amplification, karyotypic and clinicopathological features. Homogeneously staining region (HSR) is the most frequent form of amplification found in breast cancer. HSR-containing tumours accounted for 60C% of the cases. Although up to 400/o of tumours with slightly altered karyotype contained HSRs, an excess of HSRs was found within the tumours whose karyotype showed the highest rates of rearranged chromosomes. HSRs were also found to be particularty frequent in small tumours of high histological grade and with a low expression of progesterone receptors. An excess of HSRs seems to be observed in younger patients, however, significant correlation could be demonstrated onty for patients below 55 years and below 60 years, compared with older ones. With a 120-month follow-up for 152 patients, a significant association between the presence of HSRs and a shortened overall survival was observed. Altogether, the presence of HSRs appears to be a good indicator of poor prognosis. Further studies are needed to determine whether amplification of specific genes or cell ability to amplify is the most important parameter for tumour progression.
Keywords: amplification; breast cancer; histological grade; survival Cytocenetic studies and clinicopathological data of breast cancer have established correlations between chromosome alterations and histolooical gradinc (Dutrillaux et al 1991 : Emerson et al. 1993 : Pandis et al. 1996 . proliferative activity (Remvikos et al. 1992) and steroid hormone receptor status ).
Other studies have also proposed a possible relationship betmeen prognosis and specific chromosome alterations. such as chromosome I rearrangements (Hainsw orth et al. 1992) or the presence of homogeneousl-staining regions (HSRs) (Zafrani et al. 1992 ).
However. most of these studies considered a limited number of cases, and their findings rarely reached statistical significance.
As proposed by Gerbault-Seureau et al (1987) and Saint-Ruf et al (1991) . HSRs. as hallmarks of gene amplification. frequently occur in breast cancer cells. Their relationship with known protooncogene amplifications. such as MYC. ERBB2 and CCNDJ. has been shown to be complex (Saint-Ruf et al. 1990) . and studies using comparative genomic hN bridization (CGH) have shown that multiple sites may be the targets of amplifications (Guan et al. 1994 : Kallionemi et al. 1994 : Muleris et al. 1994a : Trent et al. 1995 . Thus. in addition to molecular studies (Bi&che and Lidereau. 1995 
Steroid receptor assays
Oestrogen (ER) and progesterone (PR) receptors were measured as previously described ) using solid phase immunoenzvmetric assays (ER-EIA and PR-EIA. Abott. USA) according to the manufacturer's recommendations. Briefly. tumour tissue samples were homogenized in a 10 m-.t Tris glvcerol (10% vX) 10 m-M sodium moly bdate. I m-tN dithiothreitol buffer containing 0.4 !I potassium chloride. After centrifugation at 105 000 g (1 h. 4 C). the supematant (cytosol) was used for ER and PR and total protein assays and the pellet for DNA assay: receptor status was stratified as follows ): 
Statistical analysis
Correlations betw-een variables w ere tested using the X test. Sur-vival curves were draw-n using the Kaplan-Meier method (Kaplan and Meier. 1958 ) and compared with the log-rank test.
RESULTS
The presence of one HSR or more per metaphase w-as detected in 129 out of 223 (58%c) Figure 1 .
Representativeness of our series The mean age of the patients in our study (58 years) was slightly higher than that of the large reference series of our institute (56 years). TNM staging of the tumours w-as also compared w-ith the reference series. In this series. 0.5%7. 15%. 48%T. 25%7c and 11.5%7c were classified as stage 0. I. Ia. Ilb and MIl respectively. while in the reference series these percentages were of 5.5%7c. 29.5%-. 30%.
23.5%7 and 11.5% respectively. These differences were due to the Cancer (1998) 78 (9) 
Histological grade
There was a strong relationship between the presence of HSRs and high histological grade, the rate of HSR+ grade 3 tumours being about threefold that of grade 1 (Table 2) .
Steroid hormone receptor status
There were more HSR+ tumours among those which had low rather than high hormone receptor expression, but the difference reached statistical significance only for progesterone receptors (X2= 7.6; v = 1; P = 0.006, Table 2 ).
Survival
The follow-up data were available for only 152 patients and ranged from 4 to 117 months. The overall survivals were 90% and 74% at 60 months for HSR-and HSR+ tumours respectively. At 110 months, the overall survivals were 74% and 54% respectively (Figure 4) . The presence of HSRs was found to be significantly associated with a shortened overall survival (X' = 4; v = 1; P = 0.04).
Disease-free survival
As shown in Figure 5 , the presence of HSR seems to be associated with a shortened disease-free survival, but the difference between HSR+ and HSR-tumours does not reach a statistical significance. Disease-free survivals were 76% and 52% at 60 months for HSRand HSR+ tumours respectively. Although not statistically significant, the presence of HSRs seemed to be related to metastatic recurrence at 48 months, but not to local recurrence (data not shown).
DISCUSSION
Gene amplification is a common alteration of breast cancer cells. Molecular studies have shown that some genes, such as ERBB2, can be amplified and overexpressed in about 30% of the cases, and suggested that such amplifications could be related to prognosis (Slamon et al, 1987; Hynes, 1993) .
DNA amplification can also be detected by cytogenetic analyses, which show that, in breast cancer, almost all amplifications are intrachromosomal and form HSRs (Gerbault-Seureau et al, 1987) . This differs from other cancers such as gliomas, in which amplified genes are frequently extrachromosomal, forming double minutes (Muleris et al, 1994b) . HSRs, in breast cancers, are frequently of a large size, accounting for more than 15% of the haploid genome per cell (Saint-Ruf et al, 1990) . This suggested that amplifications either lead to very high numbers of copies of target DNA sequences, or that multiple sequences can be coamplified. Studies by CGH (Kallioniemi et al, 1994; Muleris et al, 1994a) provided a partial answer, showing that multiple chromosome bands could be involved in amplification in a given tumour with up to five different origins being detected in a single HSR (Guan et al, 1994; Muleris et al, 1995) . This raises a number of questions about the meaning of these amplifications. Do they occur early during tumour genesis or are they a common event occurring during tumour progression? In the first eventuality, do they correspond to a special mechanism influencing tumour growth, metastatic potential and prognosis? This study was conducted to answer these questions.
Our study showed that a proportion of HSRs occur in tumours with minimal chromosome alterations: about 40% of tumours with less than 20% of rearranged chromosomes are HSR carriers. This suggests that HSRs can be fonned during the early phase of tumour development However, the strong correlation between the presence of HSRs and the rate of rearranged chromosomes per tumour shows that HSRs, which can occur early, are also formed during tumour progression. Thus, the amplification process occurs early and continues during tumour progression. The relationship between the presence of HSRs and age at tumour onset is of interest. Whatever the cut-off in relation to the age, HSR+ tumours are always more frequent in younger than in older patients, but the excess in younger patients reaches statistical significance at 55 and 60 years cut-off only. Among other interpretations, this could mean that breast cancers in post-menopausal patients have a lower tendency to form gene amplification. The effect of ageing on HSR incidence is, however, difficult to demonstrate because of the low number of cases in each age group. Surprisingly, the probability of the presence of HSR was found to be inversely related to tumour size. Indeed. this may be also related to age, larger tumour sizes being observed in older patients, but it strongly suggests that tumour progression is quite different in young and old patients.
The strongest relationship with a pathological parameter was found between the presence of HSRs and high histological grade. The presence of HSRs was also found to be related to the loss of steroid hormone receptor expression and, in particular, to that of progesterone receptors, the highest rate of HSRs being observed in ER+/PR-and ER-/PR-tumours. The presence of HSRs appeared to be independent of axillary nodal status.
It remains to be determined whether the relationship with prognosis concerns the amplification process in general or is related to the involvement of specific genes. Unfortunately, there are no strong data to answer this question. Interpretation of the prognostic value of ERBB2 amplification is controversial (Hynes and Stem, 1994) . It is now admitted that it is associated with a poor prognosis in node-positive patients only (Noguchi et al, 1992; Marks et al, 1994 ). We do not know which of our HSR+ tmiou had an ERBB2 amplification, but we expect that a high proportion of them had it because the incidence of ERBB2 amplification in nonselected cases is 20-30% (Brison, 1993) .
Thus, a HSR+ tumour is typically of small size and occurs in younger patients with high histological grade disease and who are progesterone receptor negative. As a matter of fact. in our series, 86% of the tumours measuring 20 mm or less, PR-and of grade 3 were HSR+. This suggests that the presence of HSRs is related to adverse prognostic factors. Such a conclusion is strengthened by the data on 5-year survival, which show a lower survival for patients with HSR+ than HSR-tunmurs.
